tiprankstipranks
Trending News
More News >
Acarix AB (SE:ACARIX)
:ACARIX

Acarix AB (ACARIX) AI Stock Analysis

Compare
1 Followers

Top Page

SE

Acarix AB

(Frankfurt:ACARIX)

Rating:46Neutral
Price Target:
Acarix AB's stock score reflects significant profitability challenges despite strong revenue growth and a robust balance sheet with no debt. Technical indicators suggest a bearish trend, and valuation metrics highlight the unprofitability of the company. The absence of dividend yield further detracts from its attractiveness. Overall, the company needs to improve its operational efficiency and profitability to enhance its stock potential.

Acarix AB (ACARIX) vs. iShares MSCI Sweden ETF (EWD)

Acarix AB Business Overview & Revenue Model

Company DescriptionAcarix AB (publ), a medical technology company, develops and commercializes diagnostic tests for cardiovascular diseases in Germany, Sweden, the Middle East, Switzerland, Austria, and internationally. The company offers CADScor System, a non-invasive and ultra-sensitive analytical device for the diagnosis of coronary artery disease. Acarix AB (publ) was founded in 2009 and is headquartered in Malmö, Sweden.
How the Company Makes MoneyAcarix AB generates revenue primarily through the sale of its CADScor System devices and related services. The company sells these diagnostic devices to healthcare providers, clinics, and hospitals, which use them to assess patients for coronary artery disease. Acarix may also generate income through service agreements or maintenance contracts linked to the ongoing use of its technology. Partnerships with healthcare institutions and collaborations with research entities can also play a role in expanding its market reach and enhancing its revenue streams.

Acarix AB Financial Statement Overview

Summary
Acarix AB demonstrates a solid revenue growth trajectory and maintains financial stability with a strong equity base and no debt. However, significant profitability challenges persist, with consistent operating losses impacting cash flow. While the company benefits from a healthy Gross Profit Margin, it needs to address its operational inefficiencies to enhance overall financial performance.
Income Statement
40
Negative
Acarix AB has shown consistent revenue growth over the years, with a notable increase from 2020 to 2021. However, the company struggles with negative EBIT and Net Income margins, indicating ongoing operational challenges and profitability issues. Despite a high Gross Profit Margin, the persistent net losses are concerning.
Balance Sheet
65
Positive
The company maintains a strong equity position with zero debt, reflected in a favorable Debt-to-Equity ratio. The Equity Ratio is robust, indicating financial stability. However, the company has been unable to leverage its assets effectively to generate profits, as seen in negative ROE.
Cash Flow
50
Neutral
Operating cash flow remains negative, pointing to ongoing operational challenges. The company has managed to improve its cash position primarily through financing activities. The Free Cash Flow to Net Income Ratio indicates that operational cash flow is not supporting profitability.
Breakdown
Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
6.20M6.24M5.82M3.76M2.17M
Gross Profit
5.59M5.30M4.62M2.82M1.59M
EBIT
-66.37M-77.55M-76.47M-51.70M-41.43M
EBITDA
-62.63M-77.12M-76.12M-50.52M-40.29M
Net Income Common Stockholders
-66.19M-77.84M-77.50M-51.80M-41.55M
Balance SheetCash, Cash Equivalents and Short-Term Investments
53.99M35.15M6.62M15.81M64.06M
Total Assets
80.76M62.88M69.48M118.60M89.95M
Total Debt
0.000.00251.00K523.00K1.37M
Net Debt
-53.99M-35.15M-6.37M-15.29M-62.70M
Total Liabilities
5.06M11.00M17.66M18.06M7.81M
Stockholders Equity
75.70M51.88M51.83M100.54M82.14M
Cash FlowFree Cash Flow
-64.25M-81.37M-75.02M-48.05M-36.69M
Operating Cash Flow
-63.33M-81.37M-74.87M-48.01M-36.69M
Investing Cash Flow
-920.00K0.00-151.00K-43.00K0.00
Financing Cash Flow
86.98M106.23M69.03M-164.00K47.35M

Acarix AB Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.24
Price Trends
50DMA
0.23
Positive
100DMA
0.23
Positive
200DMA
0.27
Negative
Market Momentum
MACD
<0.01
Negative
RSI
57.45
Neutral
STOCH
35.62
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ACARIX, the sentiment is Positive. The current price of 0.24 is above the 20-day moving average (MA) of 0.23, above the 50-day MA of 0.23, and below the 200-day MA of 0.27, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 57.45 is Neutral, neither overbought nor oversold. The STOCH value of 35.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:ACARIX.

Acarix AB Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
54
Neutral
$5.38B3.40-45.06%3.28%16.75%-0.02%
46
Neutral
kr255.83M-88.97%-0.61%54.19%
DE5J3
€11.77M-209.61%
DE2OK
€18.36M-20.45%
DE6Y1
€41.18M-19.17%
DE3F8
€25.76M-159.24%
DE5YL
€37.56M-33.54%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SE:ACARIX
Acarix AB
0.24
-0.09
-26.54%
DE:5J3
SciBase Holding AB
0.02
0.01
100.00%
DE:2OK
SpectraCure AB
0.01
-0.07
-87.50%
DE:6Y1
Integrum AB Class B
1.88
-3.16
-62.70%
DE:3F8
Q-linea AB
0.04
-0.01
-20.00%
DE:5YL
BrainCool AB
0.13
-0.05
-27.78%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.